Sugi Predict

Sugi Predict / Compounds / SCHEMBL24327468

SCHEMBL24327468

SCHEMBL24327468

CS(=O)(=O)N1CCc2cccc(Nc3nc(Cl)ncc3Cl)c21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK9 P50750 6/20 0.43
▸ CDK7 P50613 4/20 0.43
▸ ALK Q9UM73 6/20 0.41
▸ AXL P30530 2/20 0.40
▸ NEK2 P51955 1/20 0.40
▸ EGFR P00533 3/20 0.40
▸ MAPK3 P27361 1/20 0.39
▸ CCNK O75909 2/20 0.39
▸ CCND3 P30281 2/20 0.39
▸ CDK6 Q00534 2/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ ROS1 P08922 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ ZAP70 P43403 1/20 0.38
▸ MET P08581 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661342 1.00 CDK9 (0.43) CDK9CDK7ALKAXLNEK2
SCHEMBL29661271 0.94 CDK9 (0.42) CDK9CDK7ALKAXLNEK2
SCHEMBL26778572 0.94 CDK9 (0.42) CDK9CDK7ALKAXLNEK2
SCHEMBL29661472 0.90 BRD4 (0.37) CDK9CDK7CCNKCCND3CDK6
SCHEMBL24327587 0.90 BRD4 (0.37) CDK9CDK7CCNKCCND3CDK6
SCHEMBL30595373 0.89 BCL6 (0.43) CDK9CDK7ALKAXLNEK2
SCHEMBL24328356 0.89 GLO1 (0.41) ALKEGFRNPC1RAB9ALRRK2
SCHEMBL25014390 0.89 CDK9 (0.40) CDK9CDK7ALKAXLNEK2
SCHEMBL29661317 0.89 ZAP70 (0.41) CDK9CDK7ALKEGFRNPC1
SCHEMBL24327315 0.89 ZAP70 (0.41) CDK9CDK7ALKEGFRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025902-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE BEONE MEDICINES I GMBH (CH) 2024-01-25 — — US disclosed
US-20240025902-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE BEONE MEDICINES I GMBH (CH) 2024-01-25 — — US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 — — US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 — — US disclosed
CN-116745280-A Bifunctional compounds for degrading EGFR and related methods of use 百济神州有限公司 2023-09-12 — — CN disclosed
WO-2022068849-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE BEIGENE, LTD. (KY) 2022-04-07 — — WO disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 CDK9 67/4885CDK7 216/4885ALK 13/4885
US-20240025902-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE EGFR, ERBB2, CBL CDK9 1312/4885CDK7 1613/4885ALK 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.